Study of a Chatbot to Improve Genetic Risk Assessment for Hereditary Cancer in Gynecology Patients
Led by Weill Medical College of Cornell University · Updated on 2026-06-23
150
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a mobile health platform called a chatbot that uses artificial intelligence and natural language processing to communicate with patients at an all-Medicaid gynecology clinic. The study aims to compare this chatbot system to usual care to see if it improves recommendations for genetic testing among patients at high risk for familial cancer syndromes. The study also seeks to understand factors that affect patient access to and use of genetic testing services, focusing on inequities.
Participants will be assigned to one of two groups. In the chatbot group, patients receive a text message to start a chatbot conversation that collects personal and family cancer history and identifies high-risk patients based on National Comprehensive Cancer Network criteria. The chatbot provides pre-test genetic counseling and notifies clinicians about high-risk patients, who then complete counseling and recommend genetic testing if appropriate. In the usual care group, clinicians collect personal and family cancer history during visits and evaluate risk according to guidelines before counseling and recommending testing. Genetic testing is ordered for interested patients meeting criteria.
Participants will be monitored over two years to measure outcomes such as the proportion of patients recommended for genetic testing and the proportion completing testing. The study also assesses patient satisfaction, distress levels, decision satisfaction, facilitators and barriers to genetic testing, and other scales related to inequity in utilization of genetic services. These evaluations include questionnaires and surveys to understand patient experiences and access to care during the study period.
CONDITIONS
Brief Title
Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment
Research Team
M
Melissa K Frey, MD, MS
E
Elise Barrow, MPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Chatbot-assisted digital risk assessment
Usual care (provider assessment)
What is it?
A digital chatbot platform designed to simulate conversation, collect family history, evaluate genetic risk with guideline algorithms, and facilitate genetic testing workflows.
Standard clinical practice involving provider-led family history review, guideline-based assessment, and genetic testing recommendation where indicated.
Role in the trial
Evaluated as the intervention arm; tests whether digital chatbot triage can increase quality and efficiency of hereditary cancer genetic risk assessment in gynecology clinics.
Serves as the comparator arm; reflects current clinical workflow for genetic risk assessment via provider review.
Primary use
Automates family history collection, applies guideline criteria to identify high-risk patients, and streamlines pre-test education and genetic testing ordering.
Provider manually reviews family history, applies medical guidelines to assess genetic testing eligibility, and educates patients as part of usual clinical practice.
How is it given or performed?
Patients interact with the chatbot on their smartphone prior to or at the clinic visit via text-style prompts; chatbot collects family history, delivers education, and facilitates testing orders if indicated.
Provider conducts in-person family history review, evaluates risk, educates patient, and orders genetic testing if guideline criteria are met.
Evidence status
Efficacy and impact on recommendations to undergo genetic testing are being actively studied; no published trial results yet, but digital risk tools have been shown to improve workflow and guideline adherence in other contexts.
Provider-led guideline-based risk assessment represents current standard practice and is effective at identifying high-risk patients, though workflow inefficiencies and documentation gaps can limit genetic testing uptake.
Important limitations
Chatbot engagement requires smartphone access, English literacy, and patient willingness to use a digital tool; patients with limited digital literacy, language barriers, or discomfort with digital assessment may experience reduced benefit or exclusion.
Provider workflow may be affected by time constraints, incomplete family history collection, or inconsistent guideline application; barriers exist in routine care for genetic testing referral, especially in underserved populations.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
8 years of age or older
Scheduled for a new patient appointment in the gynecology clinic
Speaks and reads English
Has access to a telephone with texting capability
Has not had prior genetic testing for hereditary cancer syndromes
You will not qualify if you...
Under 18 years of age
Has had previous genetic testing for hereditary cancer syndromes
Does not read or speak English
Does not have access to a phone with texting capabilities
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or virtual)
Intervention
Duration - Up to 2 years
Participants either engage with a chatbot that collects personal and family cancer history and provides pre-test genetic counseling or receive usual care where clinicians collect history and counsel during visits.
Visits occur during routine clinical appointments
Follow-up
Duration - Up to 2 years
Researchers monitor outcomes such as genetic testing recommendations, completion rates, patient satisfaction, distress, decision satisfaction, and barriers to testing over two years.
Questionnaires and surveys at scheduled intervals
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Similar Trials
Study of Using 3D-Printed Custom Devices for High-Dose Radiation Treatment in Gynaecological Cancer
Using 3D Ultrasound to Guide Needle Placement in Brachytherapy for Advanced or Recurrent Gynecologic Cancers
Phase 1 Study of CD70-targeted CAR-T Cells for Advanced or Metastatic CD70-positive Gynecologic Cancer
Phase I Study Evaluating Safety and Effectiveness of GC203 Engineered Tumor Infiltrating Lymphocytes for Advanced Malignant Solid Tumors
Observational Study of Advanced Pelvic Cancer Surgery Outcomes at Glasgow Royal Infirmary
Observational Study of Advanced Radiotherapy Techniques in Women with Gynecologic Cancer Evaluating Treatment Outcomes and Toxicity
Comprehensive Molecular Profiling and Clinical Data Analysis for Cancer Patients and Those at Risk in a Community Healthcare Setting
Phase II Study of Belzutifan for Recurrent or Persistent Clear Cell Carcinoma in Female Gynecologic Cancers
BOLSTER Program to Support Patients and Caregivers Facing Advanced Gynecologic and Gastrointestinal Cancers
Pilot Study of Brodalumab to Treat Immune-Related Side Effects in Adults with Advanced Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Protocol for Health Risk Information Technology-Assisted Genetic Evaluation (HeRITAGE): a randomised controlled trial of digital genetic cancer risk assessment in a diverse underserved gynaecology clinic.